References
- Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral pre exposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367(5):423-34
- Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365(6):493-505
- Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366(14):1275-86
- Doria-Rose NA, Schramm CA, Gorman J, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014;509(7498):55-62
- Bachler BC, Humbert M, Palikuqi B, et al. Novel biopanning strategy to identify epitopes associated with vaccine protection. J Virol 2013;87(8):4403-16
- Ackerman ME, Crispin M, Yu X, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest 2013;123(5):2183-92
- Travers SA. Conservation, compensation, and evolution of n-linked glycans in the hiv-1 group m subtypes and circulating recombinant forms. ISRN AIDS 2012;2012:823605
- Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol 2013;20(7):804-13
- Kong L, Lee JH, Doores KJ, et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol 2013;20(7):796-803
- Alam SM, Dennison SM, Aussedat B, et al. Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proc Natl Acad Sci USA 2013;110(45):18214-19
- Amin MN, McLellan JS, Huang W, et al. Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies. Nat Chem Biol 2013;9(8):521-6
- Krammer F, Cox RJ. The emergence of H7N9 viruses: a chance to redefine correlates of protection for influenza virus vaccines. Expert Rev Vaccines 2013;12(12):1369-72
- Kramer VG, Siddappa NB, Ruprecht RM. Passive immunization as tool to identify protective HIV-1 Env epitopes. Curr HIV Res 2007;5(6):642-55
- Wilson IA, Cox NJ. Structural basis of immune recognition of influenza virus hemagglutinin. Annu Rev Immunol 1990;8:737-71
- Medina RA, Stertz S, Manicassamy B, et al. Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses. Sci Transl Med 2013;5(187):187ra70
- Longini IM, Halloran ME, Nizam A, et al. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. Vaccine 2000;18(18):1902-9
- Mendelman PM, Cordova J, Cho I. Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults. Vaccine 2001;19(17-19):2221-6
- Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372(9653):1881-93
- Hammer SM, Sobieszczyk ME, Janes H, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013;369(22):2083-92
- Hertz T, Ahmed H, Friedrich DP, et al. HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. PLoS Pathog 2013;9(6):e1003404
- Kunwar P, Hawkins N, Dinges WL, et al. Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine design. PLoS One 2013;8(5):e64405
- Kuwata T, Takaki K, Yoshimura K, et al. Conformational epitope consisting of the V3 and V4 loops as a target for potent and broad neutralization of simian immunodeficiency viruses. J Virol 2013;87(10):5424-36
- Muhle M, Hoffmann K, Löchelt M, Denner J. Immunisation with foamy virus Bet fusion proteins as novel strategy for HIV-1 epitope delivery. Immunol Res 2013;56(1):61-72
- Correia BE, Bates JT, Loomis RJ, et al. Proof of principle for epitope-focused vaccine design. Nature 2014;507(7491):201-6
- Sundaramurthi JC, Swaminathan S, Hanna LE. Resistance-associated epitopes of HIV-1C-highly probable candidates for a multi-epitope vaccine. Immunogenetics 2012;64(10):767-72